(b) Question does not arise.

(c) and (d) Yes, Sir. Eqorts are on to increase the share of Health and Family Welfare Sector further during 8th Five Year Plan.

Statement

Pattern of Investment on Health and Family Welfare (plan Outlays/Expenditure) duting the 5th, 6th and 7th plans in Public Sector-Centre, States and UTs.

(Rs. in Crores)

Period	Total plan Investment Outlay (All Heads of Development)	Health Programmes	Family Welfare Programmes	Total (3+4)
5th plan (1974—79) actuals	39426.2 (100%)	760.8	491.8	1256.6 (3.2%)
6th plan (1980—85) actuals	109291.7 (100%)	2028.7	1383.5	3412.2 (3.1%)
7th plan (1985—90) outlay	180000.0 (100%)	3392.89	3256.26	6649.15 (3.7%)

Marketing of Avapyrazone, Catopril, Pancretine, Glipizide and Oxyfedrine Hcl

1650. SHRI M. KADHARSHA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(c) whether any of these drugs are zone, Catopril, Pancretine, Glipizide and Oxyfedrine Hcl are allowed for Marketing in India;

(b) what are the symptoms for which each has been cleared;

(c) whether any of these drugs are being imported in the country;

(d) if so, the names of the drugs and, the quantity of each imported during the last three years, year-wise; and

(e) what was the CIF value of import of each drug during each year?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) Yes, Sir.

(b) The drugs mentioned in the question are cleared for following symptoms:—

1. Avapyrazone—Spasmodic pain In G-i (Gastro-intestinal), Coronary, urogenital tracts.
2. Captopril—Hypertension.
3. Pancretine—Dyspepsis, malabsorption and indigestion syndrome.
4. Glipizide—Diabetis
5. Oxyfedrine Ccl.—Angina Pactoris, Cornorary insufficiency Myocardial infarction.

(c) to (e) Information available with this Ministry is Annexed. [*See* **Appendix CL, Annexure No. 75]**